G1 Therapeutics, Inc. (GTHX)

NASDAQ: GTHX · IEX Real-Time Price · USD
5.99
+0.82 (15.86%)
Jul 5, 2022 4:00 PM EDT - Market closed

Company Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer.

The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer.

In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer.

The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD.

for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses.

G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc.
G1 Therapeutics Logo
Country United States
Founded 2008
IPO Date May 17, 2017
Industry Biotechnology
Sector Health Care
Employees 148
CEO Mark Velleca

Contact Details

Address:
700 Park Offices Drive
Research Triangle Park, North Carolina 27709
United States
Phone 919 213 9835
Website g1therapeutics.com

Stock Details

Ticker Symbol GTHX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001560241
CUSIP Number 3621LQ109
ISIN Number US3621LQ1099
Employer ID 26-3648180
SIC Code 2834

Key Executives

Name Position
John E. Bailey Jr. Chief Executive Officer, President and Director
Jennifer K. Moses CPA Chief Financial Officer
Dr. Mark A. Velleca M.D., Ph.D. Senior Advisor and Director
Dr. Rajesh K. Malik Ch.B., M.B., M.D. Chief Medical Officer and Senior Vice President of Research & Development
Mark Avagliano Chief Business Officer
Andrew Perry Chief Commercial Officer
Terry L. Murdock Chief Operating Officer
Alexander D. Smith M.S. Vice President of Technical Operations
Dr. Jay C. Strum Ph.D. Chief Scientific Officer
William C. Roberts Vice President of Investor Relations and Corporate Communications

Latest SEC Filings

Date Type Title
Jun 24, 2022 8-K Current report
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 4 Statement of changes in beneficial ownership of securities
Jun 24, 2022 S-8 Securities to be offered to employees in employee benefit plans
May 4, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 4, 2022 8-K Current report
May 4, 2022 EFFECT Notice of Effectiveness